Task: Answer Verification
Input (English): Question: Does zoledronic acid improve clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial?
Answer: ZOL given with CAB as initial treatment delays the time-to-PSA failure in patients with hormone-naive bone metastatic prostate cancer.
Output (English): yes